Standard BioTools Stock

Standard BioTools Net Debt / EBITDA

The Net Debt to EBITDA of Standard BioTools (LAB) as of Aug 24, 2026 is 1.95. In the previous year, Net Debt to EBITDA was 0.95 — a change of 105.81% (higher).

Net Debt / EBITDA

1.95

YoY

105.81%

Last updated:

Net Debt to EBITDA of Standard BioTools is 2026 1.95 . Net Debt to EBITDA of Standard BioTools was 2025 0.95 . It decreases by 105.81% higher compared to the previous year.

The Standard BioTools Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
-2.26 USD
Jan 1, 2018
-1.61 USD
Jan 1, 2019
0.08 USD
Jan 1, 2020
0.28 USD
Jan 1, 2021
-0.63 USD
Jan 1, 2022
0.53 USD
Jan 1, 2023
0.66 USD
Jan 1, 2024
1.67 USD
The Standard BioTools Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
1.67+151.28%
0.66+24.21%
0.53-184.81%
-0.63-322.56%
0.28+265.61%
0.08-104.80%
-1.61-28.69%
-2.26+22.17%
-1.85-6.84%
-1.99+28.52%
-1.55-152.64%
2.94-11.84%
3.33+1,078.36%
0.28-134.14%
-0.83-221.51%
0.68
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Net Debt to EBITDA of Standard BioTools is 1.95 in 2026.

Net Debt to EBITDA of Standard BioTools changed from 0.95 to 1.95, representing a 105.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Standard BioTools with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Standard BioTools

All Key Metrics — Standard BioTools